Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner
IRLAB Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Stock Price

KR13.1

2024-10-29

Market Capitalization

KR678.4 M

2024-10-29

Revenue

KR57.5 M

FY, 2025

CreditSafe Score

?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

SEKFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022FY, 2023FY, 2024FY, 2025
Revenue18.0K26.0K207.8M61.1M5.7M94.6M57.5M
Gross profit196.0K448.0K404.0K207.9M61.3M5.7M112.4M62.8M
Gross profit margin, %1088.9%1723.1%100.1%100.2%100.7%118.8%109.3%
Operating expense total72.8M93.4M89.6M151.9M169.6M182.2M182.5M145.5M
Depreciation and amortization1.3M2.9M2.3M3.5M4.8M4.3M4.6M4.3M
EBITDA(72.6M)(92.9M)(89.2M)56.1M(108.3M)(176.4M)(70.0M)(82.7M)
EBITDA margin, %-403138.9%-357369.2%27.0%-177.2%-3107.6%-74.0%-143.9%
EBIT(73.9M)(95.8M)(91.5M)52.6M(113.1M)(180.8M)(74.6M)(87.0M)
EBIT margin, %-410538.9%-368646.2%25.3%-185.0%-3183.6%-78.8%-151.4%
Interest income2.5M1.4M
Interest expense202.0K272.0K196.0K370.0K297.0K199.0K10.5M18.0M
Pre tax profit(74.1M)(96.1M)(91.7M)51.8M(113.4M)(177.8M)(83.1M)(110.0M)
Net Income(74.1M)(96.1M)(91.7M)51.8M(113.4M)(177.8M)(83.1M)(110.0M)

Footer menu